Neuberger Berman Group’s Black Diamond Therapeutics BDTX Stock Holding History

Neuberger Berman Group’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.4K	Buy	+10,473	New	+$25.6K	﹤0.01%	2324

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Neuberger Berman Group's BDTX Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 10,473 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #2324 among its holdings.

96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Neuberger Berman Group held 10,473 shares of Black Diamond Therapeutics worth $19.4K as of Q2 2026.
Black Diamond Therapeutics was a new Neuberger Berman Group position in Q2 2026.
Black Diamond Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2324 holding.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.